Treatment Of Nematode Infections Research Articles

Effect of sex and genotype of the host on the anthelmintic efficacy of albendazole microcrystals, in the CBi-IGE Trichinella infection murine model.

Albendazole (ABZ) is an anthelmintic pharmaceutical commonly used in the treatment of nematode infections. It is a Class II drug poorly water-soluble, with very low bioavailability, a feature particularly limiting to treat the trichinellosis chronic phase. Microcrystals obtained by controlled precipitation using hydroxyethyl cellulose and chitosan have previously been shown to improve ABZ biopharmaceutical properties. This investigation aimed to test the systems' in vivo efficacy in the CBi-IGE murine model of Trichinella spiralis infection in the infection's different phases and parasite’ stages. Treatment in the enteral phase led to a 90% decrease in the larval muscle load, probably due to its effect on T. spiralis female fecundity. Both microcrystal systems given in the migratory phase halved muscle load in males, a response not observed in females. The chitosan-based microcrystals proved to be the best when administered in the chronic phase of the infection – an increased proportion of L1 dead larvae was found compared to controls, except in CBi+-treated females. Males and females from the highly susceptible CBi+ line presented a significantly different treatment response in this phase. In vivo efficacy depended on the host genotype and sex and was related to the parasite cycle stage in which the formulations were administered.

A randomized, blinded, controlled, multi-centered field study assessing the treatment of gastrointestinal nematode infections in cats with fluralaner plus moxidectin spot-on solution (Bravecto\xae Plus)

BackgroundA spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary.MethodsTo be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later.ResultsThere were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions.ConclusionsThis field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.

Drug resistance in nematodes: a paper tiger or a real problem?

The purpose of this review is to illustrate where drug resistance in parasitic nematodes has become a major problem. The mechanisms underlying anthelmintic resistance, the possible reasons for the development of anthelmintic resistance, and recommendations to minimize the further development of anthelmintic resistance in humans will be addressed. Resistance has developed to all drugs of the few anthelmintic classes currently available. Drug resistance has become a major threat to sheep production in Australia, New Zealand, Great Britain and South Africa. In addition, the treatment of nematode infections in horses has become insufficient because of anthelmintic resistance, whereas resistance in cattle has recently been found in New Zealand and southern America. In contrast, anthelmintic resistance to human helminths has only been reported anecdotally. The rate of development of anthelmintic resistance is determined by the resistance gene frequency and by selection pressure, as illustrated by the concept of 'worms in refugia' in ovine nematode infections. Although anthelmintic resistance has become a major constraint in livestock production of small ruminants, drug resistance is currently not a major issue in the treatment of human nematode infections. However, if recent community treatment programmes are pursued injudiciously, the inevitable evolutionary consequence of anthelmintic resistance in humans might emerge sooner rather than later.

The polyanthelmintic action of dithiazanine iodide; verification of its effectiveness in the most common helminthiases in Guatemala.

Summary and Conclusions The polyanthelmintic efficacy of dithiazanine iodide was proved in the treatment of nematode infections which are most prevalent in Guatemala: Ascaris, Trichuris, Uncinaria, and Strongyloides. Dithiazanine iodide was found to be effective in 80% of the cases infected with Hymenolepis nana. Among cestodes H. nana has the greatest incidence in Guatemala. The therapeutic results obtained in cases of Taenia saginata and Hymenolepis diminuta were not satisfactory. Cooperation from the patients was excellent; the cases rejected in this evaluation because of failure to complete the course of treatment was less than 5%. The polyvermicidal action of dithiazanine iodide permits an effective treatment of single or multiple infections in ambulatory patients attending public health dispensaries and in those treated in private practice. Emphasis should be placed on the fact that for an adequate anthelmintic treatment, it is necessary to carry out quantitative examinations of feces. We prefer the Stoll technic because of its simplicity and accuracy.